Speedel Pharma Ltd. Report issue

For profit Phase 2 Phase 3
Founded: Basel Switzerland (1998)
Status: Acquired by Novartis (2008)

Organization Overview

First Clinical Trial
2003
NCT00074620
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Speedel Bio Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

Avosentan (1 trial)

Drugs in Phase 2 Trials (2)

polyethyleneglycol-hirudin (1 trial)

spp635 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Albuminuria (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Nephropathies (Phase 3)

Graft Occlusion, Vascular (Phase 2)

Hypertension (Phase 2)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Renal Insufficiency (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 3